Showing results (371-380 of 422) with videos related to

Sort By:
Pageof 43
Frontiers in Immunology|July 12, 2023
Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomesLilit Karapetyan, Hassan M AbuShukair, Aofei Li, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
The Journal of Infectious Diseases|February 25, 2016
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody ResponseAnna P Durbin, Beth D Kirkpatrick, Kristen K Pierce, et al.
The Journal of Infectious Diseases|March 25, 2015
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive AdultsBeth D Kirkpatrick, Anna P Durbin, Kristen K Pierce, et al.
Therapeutic Advances in Medical Oncology|April 22, 2020
Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancerDavid W Doo, Selene Meza-Perez, Angelina I Londoño, et al.
Journal of Translational Medicine|November 18, 2017
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016Paolo A Ascierto, Sanjiv S Agarwala, Gennaro Ciliberto, et al.
Communications Biology|January 13, 2022
Lysoptosis is an evolutionarily conserved cell death pathway moderated by intracellular serpinsCliff J Luke, Stephanie Markovina, Misty Good, et al.
The Lancet. Oncology|February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 studyReinhard Dummer, Jun Guo, Jason J Luke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 StudyJason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2025
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 studyJason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.
Pageof 43